BDNF, neuroplasticity, and anxiolytic mechanisms in nootropic peptide research
Semax and Selank are synthetic peptides developed from ACTH and tuftsin respectively, with substantial preclinical and limited clinical evidence for nootropic and anxiolytic effects. Both peptides are administered primarily via intranasal spray due to direct transport along the olfactory nerve to central nervous system structures. Research focuses on upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), modulation of the GABAergic system, and regulation of monoamine neurotransmitters.
Semax (MEHFPGP) is an ACTH(4-7) analogue that upregulates BDNF and NGF expression in the hippocampus and cortex, enhances dopaminergic and serotonergic tone, and reduces oxidative stress markers. Selank (TKPRPGP) is a tuftsin analogue that modulates GABAergic transmission (particularly GABA-A receptor subunit expression), suppresses IL-6 and TNF-α, and reduces anxiety indices in multiple validated behavioural paradigms.
| Protocolo | Peptídeos | Duração | Dosagem | Ponto final |
|---|---|---|---|---|
| Morris Water Maze (Spatial Memory) | Semax | 14 days | 50–200 µg per animal (mouse); 0.1 mg/kg (rat) · Once daily, intranasal | Escape latency (seconds), platform quadrant dwell time during probe trial, BDNF mRNA (qPCR) in hippocampal tissue at sacrifice |
| Elevated Plus Maze (Anxiety) | Selank | 7 days | 100–300 µg per animal · Once daily, intranasal or SC | Open-arm time (%), open-arm entries (%), serum corticosterone (ELISA), hippocampal BDNF protein (Western blot) |
| 14-Day BDNF Upregulation Study | Semax, Selank | 14 days | 100 µg per animal per dose · Twice daily | Hippocampal and prefrontal BDNF protein (ELISA), TrkB phosphorylation (Western blot), open-field locomotion (to control for sedation) |
Selank significantly upregulated genes involved in GABA-A receptor subunit expression and BDNF in rat prefrontal cortex after 5-day intranasal treatment, correlating with anxiolytic behaviour in EPM and light-dark box tests.
PMID 20857282Intranasal Semax produced a 2.5–3× increase in BDNF mRNA and protein in the hippocampus and frontal cortex of healthy rats at 24 and 72 hours post-administration.
PMID 16466354✓Prós
- Nasal spray delivery — no injections required, lower barrier than most peptide categories
- Selank shows anxiolytic potency comparable to benzodiazepines in animal models, without sedation or withdrawal
- Semax demonstrates 2–3× increase in hippocampal BDNF in published rodent studies
- Both compounds have been used clinically in Russia with decades of post-marketing observation
- Fast onset for anxiolytic effects: animal models show reduced anxiety within 30–60 minutes of intranasal dosing
- Cognitive and mood effects often reported together — broad neurological profile from two compounds
×Contras
- Most human trial data comes from Russian-language studies, many not available in peer-reviewed Western journals
- Short half-life requires consistent twice-daily dosing — missed doses disrupt the protocol
- Nasal absorption varies significantly between individuals based on mucosal health and dosing technique
- No Western regulatory approval (FDA, EMA)
- Limited EU vendor availability compared to healing peptides — stock issues are common
- Subjective effects can be subtle; self-researchers report highly variable responses
Why is intranasal the preferred route for Semax and Selank?
Intranasal delivery exploits the olfactory nerve pathway for direct CNS transport, achieving CSF concentrations significantly higher than equivalent IV doses. Both peptides are rapidly degraded peripherally, making direct CNS delivery critical for central effects.
How do Semax and Selank differ mechanistically?
Semax primarily drives BDNF/NGF expression and enhances monoaminergic (dopamine, serotonin) signalling — making it more relevant to cognitive enhancement and neuroprotection research. Selank acts predominantly on the GABAergic system and cytokine regulation, making it more relevant to anxiety and neuroimmune research.
Mais desta região.
Outros artigos que cobrem os fornecedores, marco regulatório e peptídeos de pesquisa desta região.